Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results